Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection.

Código QR

Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection.

Guardado en:

Detalles Bibliográficos
Autores principales:	Morgane Rolland, Peter B Gilbert
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/5449a9ffa95a453d8fceac090556c536
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies
por: Chaojie Zhong, et al.
Publicado: (2021)

Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters
por: Rebecca L. Brocato, et al.
Publicado: (2021)

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
por: Samir Andrade Mendonça, et al.
Publicado: (2021)

Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in Deficiency
por: Maaz Jalil DO, et al.
Publicado: (2021)

Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2
por: Hansam Cho, et al.
Publicado: (2021)

The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal
por: Eduardo Tosta
Publicado: (2021)

Viral vector-based vaccines against SARS-CoV-2
por: Kenneth Lundstrom
Publicado: (2021)

Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern
por: Antonio J. Martín-Galiano, et al.
Publicado: (2021)

MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge
por: Clement A. Meseda, et al.
Publicado: (2021)

Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic
por: Charles Yap, et al.
Publicado: (2021)

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
por: Susanne Rauch, et al.
Publicado: (2021)

Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
por: Fuxing Lou, et al.
Publicado: (2021)

SARS‐CoV‐2 spike glycoprotein‐reactive T cells can be readily expanded from COVID‐19 vaccinated donors
por: Pavla Taborska, et al.
Publicado: (2021)

A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern
por: Mitch Brinkkemper, et al.
Publicado: (2021)

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
por: Nikolaos C. Kyriakidis, et al.
Publicado: (2021)

The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity
por: Carlos del Fresno, et al.
Publicado: (2021)

Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters
por: Qingmei Jia, et al.
Publicado: (2021)

Considering Frailty in SARS-CoV-2 Vaccine Development: How Geriatricians Can Assist
por: Andrew MK, et al.
Publicado: (2021)

Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
por: Ian McDonald, et al.
Publicado: (2021)

Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination
por: Rafael Assis, et al.
Publicado: (2021)

Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
por: Yandi Zhang, et al.
Publicado: (2021)

Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine
por: Felipe Melo-González, et al.
Publicado: (2021)

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
por: Glenn A. Marsh, et al.
Publicado: (2021)

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
por: Jing Zou, et al.
Publicado: (2021)

A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19
por: Delphine C. Malherbe, et al.
Publicado: (2021)

Intranasal gene therapy to prevent infection by SARS-CoV-2 variants.
por: Joshua J Sims, et al.
Publicado: (2021)

Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
por: Joan E. M. van der Lubbe, et al.
Publicado: (2021)

A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection
por: Claudio Counoupas, et al.
Publicado: (2021)

Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients – the Vienna Cohort
por: Georg Beilhack, et al.
Publicado: (2021)

Tear antibodies to SARS‐CoV‐2: implications for transmission
por: Kevin J Selva, et al.
Publicado: (2021)

Interactions of SARS-CoV-2 envelope protein with amilorides correlate with antiviral activity.
por: Sang Ho Park, et al.
Publicado: (2021)

In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.
por: Agnieszka M Szemiel, et al.
Publicado: (2021)

Transmission of SARS-CoV-2 in domestic cats imposes a narrow bottleneck.
por: Katarina M Braun, et al.
Publicado: (2021)

Exacerbated innate host response to SARS-CoV in aged non-human primates.
por: Saskia L Smits, et al.
Publicado: (2010)

Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation
por: Lauren M. Meyers, et al.
Publicado: (2021)

Understanding protection from SARS-CoV-2 using metabolomics
por: Elettra Barberis, et al.
Publicado: (2021)

Harnessing early life immunity to develop a pediatric HIV vaccine that can protect through adolescence.
por: Ria Goswami, et al.
Publicado: (2020)

Temporal dynamics of SARS-CoV-2 mutation accumulation within and across infected hosts.
por: Andrew L Valesano, et al.
Publicado: (2021)

SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?
por: Wilson Lewis Mandala, et al.
Publicado: (2021)

An outbreak of SARS-CoV-2 with high mortality in mink (Neovison vison) on multiple Utah farms.
por: Chrissy D Eckstrand, et al.
Publicado: (2021)